Psychopharmacologic Therapies for Irritable Bowel Syndrome.

Gastroenterol Clin North Am

Drossman Center for the Education and Practice of Biopsychosocial Care, UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, NC 27517, USA; The Rome Foundation, Raleigh, NC, USA, and Drossman Gastroenterology, Durham NC, USA.

Published: September 2021

Psychopharmacologic therapies are beneficial in reducing symptoms when treating irritable bowel syndrome (IBS) and other disorders of gut-brain interaction (DGBI). Noradrenaline, serotonin, and dopamine are neurotransmitters of key importance in psychopharmacology and pain-reduction mechanisms. The first-line (tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, selective serotonin reuptake inhibitors) and second-line (atypical antipsychotics, delta-ligand agents, low-dose naltrexone) neuromodulator treatment options are recommended when IBS-associated abdominal pain is of moderate or severe intensity and is persistent. To understand the implementation strategy, the multidimensional clinical profile as a template is used for presenting 3 case scenarios involving painful IBS and DGBI of varying complexity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gtc.2021.04.005DOI Listing

Publication Analysis

Top Keywords

psychopharmacologic therapies
8
irritable bowel
8
bowel syndrome
8
reuptake inhibitors
8
therapies irritable
4
syndrome psychopharmacologic
4
therapies beneficial
4
beneficial reducing
4
reducing symptoms
4
symptoms treating
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!